Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
About this episode
This episode features expert discussions on the evolving management of prostate cancer, including hormone-sensitive and metastatic cases.
Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12) Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54) Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49) Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12) Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26) CME information and select publications
More episodes of Prostate Cancer Update
- Androgen Deprivation Therapy for Prostate Cancer — An Interview with Dr Rana R McKay
- For Oncology Nurses: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from the 2026 Annual ONS Congress
- Urothelial Bladder Cancer — Year in Review Series on Relevant New Datasets and Advances
- Prostate Cancer — Fifth Annual National General Medical Oncology Summit
- Urothelial Bladder Cancer — Fifth Annual National General Medical Oncology Summit
Explore listener stats, chart rankings, contacts and more on the Prostate Cancer Update podcast page.